As a new-type foreign trade service provider driven by both technology transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of β-nicotinamide mononucleotide from multiple well-known original manufacturers. As a foreign trade service provider with R&D capabilities, HiSiaddi has repeatedly collaborated with factories on technology transformation and accurately captured market demands to propose formula optimization and application improvement solutions for β-nicotinamide mononucleotide products. Below is a case of formula optimization consulting services for β-nicotinamide mononucleotide products delivered by HiSiaddi. Contact HiSiaddi customer service for more formula optimization consulting services.
The cooperating enterprise is Eternal Life, a premium biotechnology firm based in Vancouver, Canada. It specializes in high-end oral anti-aging capsules, liposome oral liquids and customized premium dietary powders for North American premium clinics. Its products are sold in private wellness hospitals, luxury organic beauty retail stores and chain functional medical clinics across North America. Its raw materials comply with USP, cGMP, Canada NPN access standards and dual KOSHER & HALAL certifications, focusing on finished high-activity full enzymatic β-nicotinamide adenine dinucleotide (β-NAD⁺) end products. Previously, it sourced high-purity raw materials from German biochemical manufacturers. To cut procurement costs and shorten supply cycles, the client independently selected a domestic biochemical factory for bulk β-NAD⁺ raw material procurement. After raw material delivery and production launch, four critical production failures emerged successively: unstable formula compatibility, sharp drops in liposome encapsulation rate, massive degradation during formulation processing, and sticking during capsule filling. Three finished product production lines were suspended, 5 batches of semi-finished products were fully scrapped, resulting in direct economic losses equivalent to CAD 17,000 and a 58-day delay in new product launch. The raw material supplier could only guarantee domestic standard purity at factory dispatch, lacking expertise in end-product compound formulation logic and formulation production process weaknesses, making targeted optimization of raw material indicators and supporting processes impossible. The client entrusted HiSiaddi to resolve all technical challenges through full-dimensional optimization covering upstream raw material modification, end-product formula adjustment and workshop production process improvement.
Mandatory performance standards for the client’s two end products:
1. Liposome oral liquid: β-NAD⁺ raw material with excellent cold water solubility; after compounding with phospholipids and citric acid, ≥93% activity retention after 6 months under normal temperature and light protection, no delamination or precipitation, and liposome encapsulation rate ≥91%;
2. Hard capsule finished products: Powder with excellent flowability to avoid sticking and blockages during automatic filling; no oxidative degradation when compounded with PQQ and ergothioneine; ≤3% degradation rate of the main component after 12 months of storage at room temperature.
Domestic manufacturers produce β-NAD⁺ using only two simple ion-exchange purification steps, leaving excessive trace nucleoside by-product impurities. When mixed with phospholipid and weak acid systems, impurities disrupt liposome bilayer structures, resulting in stratification and white flocculent precipitation after 20 days of storage. Liposome vesicles rupture and active ingredients leach, with measured encapsulation rates plummeting from the factory-stated 92% to 59%, failing end-product market access standards.
The NAD⁺ molecule readily hydrolyzes and degrades under heat and humidity. The client’s wet granulation process operates at 55°C, causing mass degradation of conventional raw materials, with finished product active ingredient content dropping by 22% relative to feeding values, failing to meet Canadian label content limit requirements.
Crude crystallization processes adopted by raw material suppliers produce irregular particle size distributions. Under the client’s Canadian workshop ambient humidity of 52%, raw materials absorb moisture and agglomerate within 3 hours of feeding, triggering frequent jams and sticking on automatic capsule filling machines, reducing production efficiency by 60% and drastically increasing waste rates.
Trace reduced intermediate impurities remain in raw materials, triggering slow oxidation reactions when compounded with PQQ and natural polyphenols. β-NAD⁺ content declines by 11.8% after 3 months of ambient storage, exceeding the brand’s internal shelf-life control limits.
HiSiaddi’s team of biochemical raw material engineers and formulation specialists collaborated with the raw material factory’s R&D department and the client’s end-product R&D laboratory to deliver rectification solutions via upstream raw material process modification, client end-product formula fine-tuning and on-site production workshop parameter optimization.
1. Upgrade to three-stage gradient chromatographic purification: Add reverse-phase chromatography purification steps to the original ion exchange process to eliminate trace nucleoside and nicotinamide by-product impurities, raising HPLC monomer purity to 99.35% and controlling total by-product impurities within 0.25%, fundamentally resolving liposome compatibility delamination and vesicle rupture issues.
2. Low-temperature crystallization + inert gas drying modification: Replace traditional hot air drying with vacuum low-temperature crystallization at ≤38°C and finished product negative-pressure drying under nitrogen protection, significantly improving heat and humidity resistance of raw materials, limiting degradation rates to ≤2% under 55°C wet granulation processing conditions.
3. Post-treatment for powder spheronization: Add trace food-grade inert anti-caking excipients to finished products and optimize particle size distribution via air flow granulation to reduce powder angle of repose, limiting moisture absorption weight gain to ≤0.8% after 72 hours under identical temperature and humidity conditions and eliminating filling agglomeration and blockage defects.
4. Precise pH endpoint adjustment: Fine-tune the pH of the final elution step to a neutral range to remove easily oxidized acidic residual intermediates and prevent oxidative losses when compounded with PQQ and polyphenols. After 5 rounds of small-batch trials and 2 medium-batch trials of 30kg each, samples passed full USP testing by third-party laboratories before shipment to Canada for re-verification by the client.
Fine-tune auxiliary material ratios within the framework of Canada’s NPN regulations without altering product efficacy positioning:
1. Liposome oral liquid formula: Add food-grade buffer salts to stabilize system pH, paired with trace antioxidant chelating agents to isolate catalytic degradation by trace metal ions, optimize phospholipid and NAD feeding ratios to stabilize liposome structures, delivering a stable finished product encapsulation rate ≥92.5%;
2. Capsule formula: Replace part of the high-moisture-absorbing lactose carrier with anhydrous microcrystalline cellulose, adopt stepwise pre-mixing feeding processes to isolate direct contact between NAD and easily oxidized active raw materials and delay oxidative losses during shelf storage.
1. Install dehumidifiers in raw material warehouse storage areas to lock ambient humidity at ≤40%; pack raw materials in argon-sealed aluminum drums for split opening and feeding to reduce large-area exposure and moisture absorption.
2. Adjust granulation processes: Adopt low-temperature dry granulation to eliminate high-temperature wet processes and reduce heat-induced raw material degradation during production.
3. Maintain filling workshop temperature below 22°C to minimize processing losses caused by ambient temperature and humidity.
The first batch of 110kg modified β-NAD⁺ raw materials was shipped to Canada after rectification, enabling seamless full production line operation for the client: liposome oral liquids showed no delamination or precipitation after 6 months at ambient temperature with compliant encapsulation rates; capsule filling proceeded smoothly without jams or sticking, with finished product activity degradation limited to only 2.1% after 12 months of storage. The high-end anti-aging new product, whose launch had been delayed for 58 days, was successfully launched for retail sales. The client finalized an annual framework procurement order of 480kg, split into 10 staggered batches for delivery throughout the year. Compared with German imported raw materials, overall procurement costs dropped by 29.6%, and ocean shipping lead times were shortened from 72 days to 28 days.
Eternal Life terminated its original German raw material supplier and fully switched its annual β-NAD⁺ raw material sourcing to domestically customized goods coordinated by HiSiaddi. The following year, the firm added customized procurement for reduced NADH and NADP, increasing annual orders by an additional 190kg. It also delegated all Chinese procurement and technical debugging for premium raw materials including NMN and ergothioneine to HiSiaddi as exclusive agent. Supported by the technical experience accumulated through this high-end customization project, the cooperating raw material factory secured follow-up customized orders from 2 mid-to-high-end wellness brands in Australia and the UK, escaping price competition for low-grade bulk NAD commodities.
Most domestic biochemical raw material manufacturers only use domestic standard factory dispatch indicators as production baselines, focusing solely on purity data without conducting compatibility testing for North American high-end formulations or R&D matching end-product oral liquid and capsule compound systems and production operating conditions. While mid-to-high-end anti-aging brands in Europe and America specialize in end-product formulation, they lack in-depth knowledge of domestic raw material production process weaknesses, leading to frequent production failures and finished product scrapping following independent procurement. Moving beyond the traditional foreign trade model of simple quotation and supply, HiSiaddi delivers full-chain technical services covering raw material process optimization, end-product formula adjustment and on-site production guidance. It helps mid-to-high-end overseas clients cut costs and resume production while supporting domestic biochemical factories in refining high-end customization processes and accessing the global supply chain of high-value coenzyme raw materials. Contact HiSiaddi customer service for more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
